Abstracts tagged "gout"

Abstract Number: 2268 • 2016 ACR/ARHP Annual Meeting
Fructose Amplifies Inflammatory Potential in Human Monocytic Cells Via Reduction of AMP-Activated Protein Kinase Activity
Xihua Cao¹, Jeffrey N. Miner², Robert Terkeltaub^3,4 and Ru Liu-Bryan^1,4, ¹VA Medical Center, San Diego, CA, ²Discovery Biology, Ardea Biosciences, Inc., San Diego, CA, ³Rheumatology, VA Medical Center, San Diego, CA, ⁴Medicine-Rheumatology, University of California, San Diego, La Jolla, CA
Background/Purpose: High dietary content of fructose (in table sugar, sweetened sodas, energy beverages, and fruit juices) is a substantial risk factor for both hyperuricemia and…
Abstract Number: 3074 • 2016 ACR/ARHP Annual Meeting
Population-Specific Association Between ABCG2 Variants and Tophaceous Disease in People with Gout
Wendy He¹, Amanda Phipps-Green², Lisa K. Stamp³, Tony R. Merriman⁴ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²University of Otago, Dunedin, New Zealand, ³University of Otago, Christchurch, New Zealand, ⁴Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand
Background/Purpose: Tophi contribute to musculoskeletal disability, joint damage and poor health-related quality of life in people with gout. The aim of this study was to…
Abstract Number: 213 • 2016 ACR/ARHP Annual Meeting
Prophylaxis for Infusion Reactions to Pegloticase: An Analyis of Two Different Corticosteroid Pre-Infusion Regimens in US Community Rheumatology Practices
Amar Majjhoo¹, Kome Okposo² and Michael Zdanis³, ¹Shores Rheumatology, St. Clair Shores, MI, ²Horizon Pharma, Lake Forest, IL, ³Cetus Group, LLC, Towson, MD
Background/Purpose: Corticosteroids are commonly utilized, along with other agents in clinical practice for pre-infusion prophylaxis prior to the administration of therapeutic biologic proteins. Two steroids,…
Abstract Number: 2272 • 2016 ACR/ARHP Annual Meeting
The Influence of Genetic Variants on Renal Uric Acid Excretion in Response to Frusemide
Nicola Dalbeth¹, Jordyn de Kwant¹, Gregory Gamble², Amanda Phipps-Green³, Anne Horne², Robert Doughty¹, Lisa K. Stamp⁴ and Tony R. Merriman⁵, ¹University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³University of Otago, Dunedin, New Zealand, ⁴University of Otago, Christchurch, New Zealand, ⁵Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand
Background/Purpose: Diuretic use is strongly associated with development of hyperuricaemia and gout. Genetic variation in the renal uric acid transporters SLC2A9 (encoding GLUT9) and SLC22A11…
Abstract Number: 3075 • 2016 ACR/ARHP Annual Meeting
Mitochondrial Genetic Variation, Copy Number and Susceptibility to Gout in the New Zealand Polynesian Population
Tony R. Merriman¹, James Boocock², Nicola Dalbeth³, Lisa K. Stamp⁴, Eli A. Stahl⁵, Hyon K. Choi⁶, Elizabeth Matisoo-Smith⁷ and Anna Gosling⁸, ¹Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ²University of Otago, Dunedin, New Zealand, ³University of Auckland, Auckland, New Zealand, ⁴University of Otago, Christchurch, New Zealand, ⁵Divisions of Rheumatology and Genetics, Brigham and Women's Hospital, Boston, MA, ⁶Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, ⁷Anatomy, University of Otago, Dunedin, New Zealand, ⁸Biochemistry, University of Otago, Dunedin, New Zealand
Background/Purpose: Mitochondria play a central role in induction of an NLRP3 inflammatory response essential for gouty pathology. Mitochondria are in part self-encoding, possessing a 16.5…
Abstract Number: 218 • 2016 ACR/ARHP Annual Meeting
Accuracy of Humasens-Plus Point-of-Care Uric Acid Meter Using Capillary Blood Obtained By Fingertip Puncture
Stephanie Fabre¹, Jean-Marie Launay¹, Jean-François Gautier¹, Adam Platt², Jeffrey N. Miner³, Glen Hughes², Pascal Richette⁴ and Thomas Bardin¹, ¹Hôpital Lariboisière, Paris, France, ²AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ³Discovery Biology, Ardea Biosciences, Inc., San Diego, CA, ⁴Fédération de Rhumatologie, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France
Background/Purpose: A key factor in the success of gout management is the long-term lowering of serum uric acid (sUA) levels below predetermined targets (5 or…
Abstract Number: 2278 • 2016 ACR/ARHP Annual Meeting
Precision of Gout Definitions for Population-Based Genetic Studies: Analysis of the UK Biobank
Murray Cadzow¹, Tony R. Merriman² and Nicola Dalbeth³, ¹University of Otago, Dunedin, New Zealand, ²Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ³University of Auckland, Auckland, New Zealand
Background/Purpose : Accurate case-definition is important for epidemiological studies of gout. However, in multipurpose cohort studies frequently used for genome wide association studies, limited information…
Abstract Number: 3139 • 2016 ACR/ARHP Annual Meeting
Breaking the Cycle: Analyzing Preventable Hospital Admissions Due to Gout
Pieusha Malhotra¹, Nikky Keer² and Robert Yood³, ¹Internal Medicine, Department of Medicine, Division of Rheumatic Diseases and Musculoskeletal Medicine, Saint Vincent Hospital, Worcester, MA, ²Internal medicine, Department of Medicine, Division of Rheumatic Diseases and Musculoskeletal Medicine, Saint Vincent Hospital, Worcester, MA, ³Department of rheumatology and musculoskeletal medicine, Department of Medicine, Division of Rheumatic Diseases and Musculoskeletal Medicine, Saint Vincent Hospital, Worcester, MA
Background/Purpose: Despite available effective treatment options and published guidelines for gout management, many patients suffer from recurrent gout attacks. Increases in gout prevalence and continued…
Abstract Number: 190 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Pharmacodynamics, and Tolerability of Verinurad, a Selective Uric Acid Reabsorption Inhibitor, in Healthy Adult Male Subjects
Michael Gillen¹, Zangong Shen² and Jeffrey N. Miner³, ¹AstraZeneca, Gaithersburg, MD, ²Ardea Biosciences, San Diego, CA, ³Discovery Biology, Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: This was a Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study. Panels of 8 male subjects (6 active, 2 placebo) received a…
Abstract Number: 219 • 2016 ACR/ARHP Annual Meeting
Presence of Monosodium Urate Crystals By Dual-Energy Computed Tomography in Gout Patients Treated with Allopurinol
Nicola Dalbeth¹, Savvas Nicolaou², Scott Baumgartner³, Jia Hu³, Maple Fung³ and Hyon K. Choi⁴, ¹University of Auckland, Auckland, New Zealand, ²Radiology, University of British Columbia, Vancouver, BC, Canada, ³Ardea Biosciences, Inc., San Diego, CA, ⁴Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Chronic hyperuricemia predisposes to deposition of monosodium urate (MSU) crystals in musculoskeletal and other tissues, causing chronic inflammation, acute gout flares, joint damage, and…
Abstract Number: 2280 • 2016 ACR/ARHP Annual Meeting
Monosodium Urate Crystal-Induced Inflammation Promotes Osteocyte Expression of Pro-Resorptive and Inflammatory Mediators: Implications for Erosive Gout
Ashika Chhana¹, Mei-Lin Tay², Bregina Pool³, Karen E. Callon², David Musson², Dorit Naot¹, Gregory Gamble³, Jillian Cornish³ and Nicola Dalbeth², ¹Medicine, University of Auckland, Auckland, New Zealand, ²University of Auckland, Auckland, New Zealand, ³Department of Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Bone erosion in gout is strongly associated with tophi; lesions comprising of inflammatory cells surrounding collections of monosodium urate (MSU) crystals. Osteocytes are…
Abstract Number: 3199 • 2016 ACR/ARHP Annual Meeting
Urate Crystal Deposition and Bone Erosion in Gout: Inside-out or Outside-in? a Dual Energy Computed Tomography Study
Patapong Towiwat¹, Anthony Doyle¹, Gregory Gamble², Paul Tan¹, Opetaia Aati², Anne Horne², Lisa K. Stamp³ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³University of Otago, Christchurch, New Zealand
Background/Purpose: Imaging and pathology studies have shown that bone erosion is closely associated with monosodium urate (MSU) crystal deposition in tophaceous gout. It is currently…
Abstract Number: 191 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Febuxostat in Healthy Adult Male Subjects
James VanderLugt¹, Michael Gillen², Xiaojuan Yang³ and Jesse Hall³, ¹Jasper Clinical Research & Development, Kalamazoo, MI, ²AstraZeneca, Gaithersburg, MD, ³Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: Verinurad (RDEA3170) is a novel selective uric acid reabsorption inhibitor in clinical development for the treatment of gout and asymptomatic hyperuricemia. This Phase 1,…
Abstract Number: 220 • 2016 ACR/ARHP Annual Meeting
Urate Lowering Therapy Regresses Ultrasound Abnormalities in Gout
Siddharth K. Das¹, Harikrishnan Velayudhan², Danveer Bhadu³, Urmila Dhakad⁴ and Ragini Srivastava⁵, ¹Rheumatology, Prof. and Head, Rheumatology, K.G. Medical University, Lucknow, Lucknow, India, ²Rheumatology, Senior Resident, Rheumatology, K.G. Medical University, Lucknow, India, Luknow, India, ³Rheumatology, Senior Resident III, Rheumatology, K.G. Medical University, Lucknow, India, Lucknow, India, ⁴Rheumatology, Asst Professor, K.G. Medical University, Lucknow, India, Lucknow, India, ⁵Rheumatology, Senior Research Officer, Rheumatology, K.G. Medical University, Lucknow, India, Lucknow, India
Background/Purpose: Detection of double contour sign (DCS) and hyperechoic aggregates (HAG) is a reliable method in detecting urate crystal deposition by ultrasound (US) which has…
Abstract Number: 2283 • 2016 ACR/ARHP Annual Meeting
Suppression of Monosodium Urate (MSU) Crystals-Induced Inflammatory Response By Inhibiting TGF-β Activated Kinase 1 (TAK1)
Anil Singh¹, Kayla O’Sullivan², Mukesh Chourasia³, Sadiq Umar⁴, Mahamudul Haque², Bhanupriya Madarampalli² and Salahuddin Ahmed², ¹Washington State University, College of Pharmacy, Spokane, WA, ²Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, ³Department of Pharmacoinformatics,, National lnstitute of Pharmaceutical Education and Research, Hajipur,, India, ⁴Department of Pharmaceutical Science, Washington State University, College of Pharmacy, Spokane, WA
Background/Purpose: Methods: Results: Conclusion:

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].